167 related articles for article (PubMed ID: 19247492)
1. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Al-Ejeh F; Darby JM; Brown MP
PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
[TBL] [Abstract][Full Text] [Related]
3. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
[TBL] [Abstract][Full Text] [Related]
4. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
Staudacher AH; Al-Ejeh F; Fraser CK; Darby JM; Roder DM; Ruszkiewicz A; Manavis J; Brown MP
EJNMMI Res; 2014 Jan; 4(1):2. PubMed ID: 24387284
[TBL] [Abstract][Full Text] [Related]
5. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
6. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
7. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
Mol Imaging Biol; 2021 Dec; 23(6):914-928. PubMed ID: 34231102
[TBL] [Abstract][Full Text] [Related]
8. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
Staudacher AH; Bezak E; Borysenko A; Brown MP
Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
10. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.
Staudacher AH; Liapis V; Wittwer NL; Tieu W; Lam HC; Leusen J; Brown MP
Biomed Pharmacother; 2022 Jul; 151():113090. PubMed ID: 35567988
[TBL] [Abstract][Full Text] [Related]
11. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution.
Al-Ejeh F; Darby JM; Thierry B; Brown MP
Nucl Med Biol; 2009 May; 36(4):395-402. PubMed ID: 19423007
[TBL] [Abstract][Full Text] [Related]
12. Proteomic characterization of EL4 lymphoma-derived tumors upon chemotherapy treatment reveals potential roles for lysosomes and caspase-6 during tumor cell death in vivo.
Kramer DA; Eldeeb MA; Wuest M; Mercer J; Fahlman RP
Proteomics; 2017 Jun; 17(12):. PubMed ID: 28508578
[TBL] [Abstract][Full Text] [Related]
13. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Zannettino AC; Findlay DM; Evdokiou A
Mol Cancer Ther; 2009 Oct; 8(10):2969-80. PubMed ID: 19808976
[TBL] [Abstract][Full Text] [Related]
14. Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®.
Liapis V; Tieu W; Rudd SE; Donnelly PS; Wittwer NL; Brown MP; Staudacher AH
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):27. PubMed ID: 33205364
[TBL] [Abstract][Full Text] [Related]
15. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Ross J; Fong S; Carano R; Totpal K; Lawrence D; Zheng Z; Koeppen H; Stern H; Schwall R; Ashkenazi A
Clin Cancer Res; 2008 Dec; 14(23):7733-40. PubMed ID: 19047100
[TBL] [Abstract][Full Text] [Related]
16. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
17. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
Al-Ejeh F; Darby JM; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5509s-5518s. PubMed ID: 17875783
[TBL] [Abstract][Full Text] [Related]
18. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
Camidge DR
Expert Opin Biol Ther; 2008 Aug; 8(8):1167-76. PubMed ID: 18613768
[TBL] [Abstract][Full Text] [Related]
19. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent.
Kemp CJ; Sun S; Gurley KE
Cancer Res; 2001 Jan; 61(1):327-32. PubMed ID: 11196181
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibody to single-stranded DNA is a specific and sensitive cellular marker of apoptosis.
Frankfurt OS; Robb JA; Sugarbaker EV; Villa L
Exp Cell Res; 1996 Aug; 226(2):387-97. PubMed ID: 8806443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
